Korsgaard S, Noring U, Povlsen U J, Gerlach J
Clin Neuropharmacol. 1986;9(1):52-7. doi: 10.1097/00002826-198602000-00005.
Serotonin (5-HT) has been proposed to exert an inhibitory effect on central dopamine activity, so increased brain 5-HT would be expected to reduce tardive dyskinesia (TD). Therefore a new antidepressant, a selective 5-HT uptake inhibitor, citalopram, was evaluated in 13 psychiatric patients with TD, 11 of whom also had neuroleptic-induced parkinsonism. Drug effects during active treatment (20-40 mg/day for 3 weeks) and pre- and posttreatment placebo periods were scored blindly from videotapes recorded weekly. TD, parkinsonism, and eyeblinking rates were unchanged. Psychiatric symptoms showed no significant changes, and no side effects were reported. The data suggest that increasing 5-HT activity by 5-HT uptake inhibitors has no significant beneficial effect in TD, but citalopram may be advantageous in the treatment of depressed patients who also have TD, as this drug does not aggravate TD as do tricyclic antidepressants.
血清素（5-羟色胺，5-HT）被认为对中枢多巴胺活性具有抑制作用，因此预计脑内5-HT增加会减轻迟发性运动障碍（TD）。为此，对一种新型抗抑郁药——选择性5-HT摄取抑制剂西酞普兰进行了评估，受试对象为13例患有TD的精神科患者，其中11例还伴有抗精神病药所致帕金森综合征。根据每周录制的录像带，在积极治疗期间（20 - 40毫克/天，持续3周）以及治疗前和治疗后的安慰剂阶段，对药物效果进行盲法评分。TD、帕金森综合征和眨眼率均未改变。精神症状无显著变化，且未报告有副作用。数据表明，通过5-HT摄取抑制剂增加5-HT活性对TD无显著有益作用，但西酞普兰在治疗同时患有TD的抑郁症患者时可能具有优势，因为该药不像三环类抗抑郁药那样会加重TD。
